Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AC Immune SA
AC Immune Third Quarter 2026 Financial and Corporate Update
November 4, 2026
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
September 23, 2026
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
August 20, 2026
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
August 20, 2026
AC Immune First Half 2026 Financial and Corporate Update
August 19, 2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 22, 2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
May 12, 2026